Chemotherapy and allo-HSCT for young patients with aggressive ATL.

Adult T-cell leukemia-lymphoma (ATL) is an aggressive malignancy with a poor prognosis, especially for patients with the aggressive subtype. While conventional chemotherapy offers short-term disease control, allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the most promising curative approach for young, transplant-eligible patients. This review focuses on current treatment strategies for aggressive ATL in this specific population. We discuss the rationale for early upfront allo-HSCT following induction chemotherapy. The advent of allo-HSCT using alternative donors, particularly haploidentical HCT, has broadened the applicability of early upfront allo-HSCT in patients with aggressive ATL worldwide. Finally, we address emerging therapies that may improve outcomes in the context of allo-HSCT, paving the way for further advancements in the treatment of aggressive ATL. • Patients with aggressive ATL have a poor prognosis with conventional chemotherapy. • There is a general consensus on early upfront allo-HSCT in patients with aggressive ATL. • Further development of pre- and post-transplant treatment and allo-HSCT is needed. [ABSTRACT FROM AUTHOR]